StockNews.com downgraded shares of iCAD (NASDAQ:ICAD – Free Report) from a hold rating to a sell rating in a research report released on Friday morning.
iCAD Price Performance
iCAD stock opened at $3.20 on Friday. iCAD has a 52 week low of $1.18 and a 52 week high of $3.78. The stock has a fifty day moving average of $2.03 and a 200-day moving average of $1.74.
Institutional Investors Weigh In On iCAD
Hedge funds and other institutional investors have recently bought and sold shares of the company. Essex LLC acquired a new position in shares of iCAD during the third quarter worth $216,000. Summit Trail Advisors LLC acquired a new position in shares of iCAD during the 4th quarter valued at $214,000. Finally, waypoint wealth counsel boosted its position in shares of iCAD by 44.0% during the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after purchasing an additional 4,400 shares in the last quarter. Institutional investors own 24.61% of the company’s stock.
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
See Also
- Five stocks we like better than iCAD
- NYSE Stocks Give Investors a Variety of Quality Options
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- How to Invest in the FAANG Stocks
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- How to Use Stock Screeners to Find Stocks
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
